Related Experiment Video
Updated: Apr 14, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Pathophysiologically relevant in vitro tumor models for drug screening
Viswanath Das1, Francesca Bruzzese2, Petr Konečný1
1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic; EATRIS Headquarters, Giovanni Migliaccio, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands.
Abstract:
The alarming rate of failure of clinical trials is a major hurdle in cancer therapy that partly results from the inadequate use of in vitro tumor models for the screening of promising hits and leads in preclinical studies. 2D cultures of cancer cell lines that are primarily used for drug screening do not adequately recapitulate tumor microenvironment (TME) complexities compared with 3D cancer cell cultures and tumor-derived primary cell cultures. In this review, we focus on the potential use of in vitro tumor models that reproduce in vivo tumor complexities for effective drug selection in the preclinical stages of drug development.
Insights
Clinical trial failures in cancer therapy are high due to poor in vitro tumor models. Advanced 3D and primary cell models better mimic tumor complexity for effective preclinical drug screening.
Area of Science:
- Oncology
- Drug Discovery
- Translational Medicine
Background:
- High clinical trial failure rates impede cancer therapy advancement.
- Current 2D cancer cell line models inadequately represent the tumor microenvironment (TME).
- This limitation impacts the efficacy of preclinical drug screening and selection.
Purpose of the Study:
- To review the potential of advanced in vitro tumor models for preclinical drug development.
- To highlight models that better recapitulate in vivo tumor complexities.
- To emphasize improved drug selection through more accurate preclinical testing.
Main Methods:
- Review of current literature on in vitro tumor models.
- Comparison of 2D cell cultures, 3D cancer cell cultures, and primary tumor-derived cell cultures.
- Analysis of the ability of different models to mimic the tumor microenvironment.
Main Results:
- 3D cancer cell cultures and primary cell cultures offer superior recapitulation of TME compared to 2D models.
- These advanced models provide a more realistic platform for evaluating drug efficacy and toxicity.
- Improved preclinical screening can lead to better candidate drug selection.
Conclusions:
- Advanced in vitro tumor models are crucial for overcoming clinical trial attrition in cancer.
- Utilizing models that mimic in vivo complexity enhances the reliability of preclinical drug screening.
- This approach promises to accelerate the development of effective cancer therapies.
